Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more.
WuXi Biologics has “temporarily paused” the construction of its new facility in Worcester, MA, as the company “reviews designs in order to optimize space utilization,” a spokesperson told Endpoints in an email. The spokesperson did not provide details as to when the construction would continue or if build timelines would be affected.
“We remain fully committed to this facility and to our presence in the City of Worcester, where we are proud to be a part of the region’s growing biomanufacturing and life sciences community,” the spokesperson said. The build, first announced in 2018, had its construction expanded in January, with the company saying it would be operational next year. It was estimated the site would add 250 new jobs in Worcester. The update was first reported by The Worcester Guardian.
Novo Holdings now has the controlling stake (about 60%) of Single Use Support, a life science tools and technology company that caters to pharma companies, biotechs and CDMOs. The two co-founders, Johannes Kirchmair and Thomas Wurm, will each retain a 10% share, while Danaher will have the remaining 20%. Single Use Support provides single-use tech to manage fluids used in making biologics, cell and gene therapies and mRNA vaccines, according to a Wednesday release.
Sartorius is expanding its collaboration with Nvidia. The partnership focuses on making AI models for stem cell-derived organoids, to be used instead of animal models in drug discovery and precision medicine, according to a Thursday release.
Retro Biosciences — the biotech that’s looking to expand average lifespans by a decade — said it is working with robotic manufacturer Multiply Labs in a pact worth $85 million. Multiple Labs will help to automate the development of Retro’s age-related approaches, the companies announced on Tuesday.
Synthetic DNA producer Elegen has raised $35 million in a Series B round. The funds will be used to further develop its product line that features strands of synthetic DNA, according to a Tuesday release.
Sartorius and Sanofi are collaborating to create a continuous downstream bioprocessing platform designed to make drug product manufacturing faster and more efficient. Sartorius will manufacture and commercialize the platform based on prototypes made by Sanofi, according to a Monday announcement. No financial details were disclosed.
Eugia Pharma Specialities was issued a Form 483 after an FDA inspection made between April 25 and May 3 at its site in Rajasthan, India. The 14-page report outlined seven observations, including deficient cleaning practices, failure to review any batch discrepancies and insufficient procedures to avoid microbial contamination.
CDMO Renaissance Lakewood has opened its headquarters in Lakewood, NJ, the company said on Tuesday.
EuroAPI has appointed Evelyne Nguyen as its new chief financial officer. Nguyen will take over from Antoine Delcour who will leave the company in June, according to a Tuesday release.